Skip to main content
Arquivos de Neuro-Psiquiatria logoLink to Arquivos de Neuro-Psiquiatria
. 2022 Dec 28;80(11):1104–1111. doi: 10.1055/s-0042-1758399

Interaction between apolipoprotein E genotypes, excessive daytime sleepiness, and cognitive function in obstructive sleep apnea patients

Interação entre genótipos da apolipoproteína E, sonolência excessiva diurna e função cognitiva em pacientes com apneia obstrutiva do sono

Fernanda Maurer Balthazar 1, Walter André dos Santos Moraes 1,, James Richard Hunter 2, Gilmar Fernandes do Prado 1, Luciane Bizari Coin de Carvalho 1
PMCID: PMC9797275  PMID: 36577409

Abstract

Background  Some studies show an association between the apolipoprotein E ε4 allele (ApoEε4) and obstructive sleep apnea syndrome (OSAS), and other studies, an association between ApoEε4 and excessive daytime sleepiness (EDS), but there are no data in the literature on the interaction between EDS, cognitive function, and ApoEε4 in patients with OSA.

Objective  To examine the cognitive function of adults with and without EDS and with and without ApoEε4.

Methods  A total of 21 male and female patients aged between 33 and 79 years, underwent a clinical interview, ApoE genotyping, neuropsychological evaluation, polysomnography, and the application of the Epworth Sleepiness Scale.

Results  Excessive daytime sleepiness was associated with lower intelligence quotient (IQ; total performance) and worse immediate visual memory, regardless of the ApoE genotype. Patients carrying the ApoEε3/ε4 genotype had a worse performance in divided attention, constructional praxis, perceptual organization, and cognitive flexibility. A combination of the ε4 allele and EDS potentiates the negative effect on cognition, except for immediate visual memory. In this case, patients had a worse performance in terms of processing speed, selective attention, and visuomotor coordination.

Conclusions  Excessive daytime sleepiness and the ApoEε3/ε4 genotype are associated with worse cognitive performance in OSA patients. The combination of EDS and ε4 allele potentiates cognitive impairment.

Keywords: Apolipoproteins E; Sleep Apnea, Obstructive; Disorders of Excessive Somnolence; Cognitive Dysfunction

INTRODUCTION

Obstructive sleep apnea syndrome (OSAS) is associated with many etiological factors, including obesity, genetic inheritance, aging, craniofacial patterns, and sedative substances. 1 2 A sleep respiratory event is a partial or complete obstruction of the upper airway during sleep that is associated with negative intrathoracic pressure, oxygen desaturation, and increased respiratory effort, leading to arousal and sleep fragmentation. 3 Patients with OSAS present important functional impairment, including cognitive deficit and excessive daytime sleepiness (EDS). 4 5 6

The apolipoprotein E (ApoE) gene is located in the long arm of chromosome 19 and presents 3 different alleles (ε2, ε3, and ε4) paired independently. 7 The ApoEε4 allele is associated with a cognitive deficit in otherwise normal individuals, age-related cognitive decline, Alzheimer disease, and cardiovascular disorders, 7 8 9 10 11 as well as OSAS in adults and children. 9 10 11 The ApoEε2 allele is considered neuroprotective and is associated with a lower age-related cognitive decline and a lesser predisposition to Alzheimer's disease. 12 The ApoEε3 allele is the most frequent in the general population, and it is considered neutral to cognitive performance. 13

The association between OSAS and EDS is well established in the literature, and EDS is considered a predisposing factor for cognitive impairment. 14 15 Patients with OSAS and EDS present impairment in attention, alertness, memory, learning, and executive function. 16 Some OSAS patients do not present EDS and cognitive impairment, suggesting that other factors may be involved in the etiology of these disturbances. 17

Some hypotheses have been proposed to explain how OSAS can affect cognitive performance independently from EDS. Several studies 18 19 20 have shown the direct association between cognitive dysfunction and OSAS. Intermittent hypoxemia can affect cognition due to neuronal damage in the cortex by increased oxidative stress. 21 Sleep fragmentation may also influence neuropsychological deficits. 14 The literature is not unanimous about the areas of cognition affected by OSAS. A meta-analysis by Wallace and Bucks 22 showed that OSAS is related to impaired episodic, verbal, and visuospatial memories. Other studies found that motor coordination, alertness, executive functions, and attention were the most affected functions. 23 24 In general, OSAS patients present long-term verbal memory and auditory working memory deficits, while OSAS patients with the ε4 allele have spatial working memory deficit. 25 A cohort study 26 found that OSAS patients with the ε4 allele have impaired memory and executive functions. Another study 10 found that children with OSAS and the ε4 allele present more intense cognitive impairment.

A study by Caselli et al. 27 showed that EDS is associated with a decline in verbal memory in ApoEε4 homozygotes compared with heterozygotes. There are no data in the literature on the interaction between EDS, cognitive function, and ApoE4 in patients with OSAS. Considering that EDS could be related to the cognitive deficit in OSAS patients with different ApoE genotypes, we have proposed this study to evaluate this hypothesis.

METHODS

Patients and ethics

In total, 36 patients were consecutively recruited in the Sleep Medicine Clinic at Neuro-Sleep Center, Department of Neurology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. All patients were submitted to baseline polysomnography (PSG). Patients with apnea-hypopnea index (AHI) > 15 were included. We did not select patients with other sleep disturbances and neurological, psychiatric, and clinical conditions that could affect cognitive performance and alertness at the discretion of the assisting physician. We did not select patients using substances that could affect cognitive function and alertness. Twelve patients were excluded because they did not meet the eligibility criteria or due to genotyping failure. The final sample was composed of 21 patients, 10 male and 11 female individuals, aged between 33 and 79 years. All patients signed a consent form. The present study was approved by the Research Ethics Committee of the Universidade Federal de São Paulo (#0494/16).

Procedure

The patients underwent a clinical interview, a physical examination, and the aplication of the Epworth Sleepiness Scale (ESS). Scores ≥ 10 on the ESS were indicative of EDS. 28 29 30 31 As aforementioned, all selected patients underwent baseline PSG. Blood samples were collected in ethylenediaminetetraacetic (EDTA) acid tubes and underwent polymerase chain reaction (PCR)-based genotyping for ApoE alleles. Genotypes ε3/ε3, ε2/ε4, and ε3/ε4 were identified in our sample. We compared patients (14) carrying the ε3/ε4 genotype with patients (7) carrying genotypes ε3/ε3 and ε2/ε4. Based on previous research, 13 in the latter group, ε2 was considered neuroprotective, ε3, neutral, and ε4, a predisposing allele.

We analyzed the neuropsychological parameters supposedly affected by OSAS. 32 The evaluation occurred in a controlled environment with adequate lighting and temperature. All neuropsychological tests were applied in a single session lasting approximately 2 hours and 30 minutes, with a 20-minute interval 90 minutes after the beginning of the evaluation. The evaluator was blinded to patient data on ESS, PSG, and ApoE. The cognitive tests applied were total intelligence quotient (IQ), verbal IQ, performance IQ, processing-speed index, symbol searching, Stroop color-word tests A, B, and C, the trail making test and the trail making test B, block design, matrix reasoning, Rey figure, forward digit span, forward and backward digit span, Rey auditory verbal learning test (RAVLT), and backward digit span. 33 34 35 36 37 The experimental procedures are summarized in Figure 1 .

Figure 1.

Figure 1

Experimental procedures.

Statistics

We calculated the means of the neuropsychological tests using gross scores for each cognitive function. The sample size was not calculated prior to the study. We normalized the results of different tests in terms of mean and standard deviation on a scale ranging from 0 to 100 and shown in a radar graph. The tests in which shorter times (in seconds) represented a better performance, the algebraic signal was inverted to be compared to the other neuropsychological parameters. We selected the Kruskal-Wallis test to compare the ε3/ε4 and non-ε3/ε4 groups for each cognitive function. The Chi-squared test was used to analyze the sociodemographic variables of gender, age, income, body mass index (BMI), and level of schooling. The Pearson correlation coefficient and Kruskal Wallis test were used to determine the influence of these variables in cognitive tests. We used the R (R Foundation for Statistical Computing, Vienna, Austria) statistical software for the statistical analysis and data management. 38 39 40

RESULTS

A total of 4 (19%) patients had genotype ε2/ε4, 3 (14.3%) had genotype ε3/ε3, and 14 (66.7%), genotype ε3/ε4. We found no significant differences between groups concerning the sociodemographic parameters ( Table 1 ), and 61.9% of the patients had ESS scores ≥ 10, and 38.1%, < 10.

Table 1. Sociodemographic parameters of the study sample (n = 21).

All genotypes ApoE ε3/ε4 non-ApoE ε3/ε4
Mean SD Mean SD Mean SD
Age 59.0 10.7 58.8 12.2 59.3 8.0
BMI 31.7 5.6 29.5 1.8 33.6 7.9
Gender Frequency Distribution Frequency Distribution Frequency Distribution
Male 10 47.6% 5 35.7% 5 71.4%
Female 11 52.4% 9 64.3% 2 28.6%
Schooling (years) Frequency Distribution Frequency Distribution Frequency Distribution
0-8 14 66,7% 10 71.4% 4 57.1%
9-12 4 19.0% 1 7.2% 3 42.9%
13-16 3 14.3% 3 21.4% 0 0%
Income group* Frequency Distribution Frequency Distribution Frequency Distribution
Low 12 57.1% 8 57.1% 4 57.1%
Medium 8 38.1% 5 35.7% 2 28.6%
High 1 4.8% 1 7.2% 1 14.3%

Abbreviations: ApoE, apolipoprotein E; BMI, Body Mass Index; SD, standard deviation.

Notes: *low: ≤ 3 monthly minimum wages; medium: 3 to 9 monthly minimum wages; high: > 9 monthly minimum wages.

The distribution of patients in groups was as follows: EDS-ε3/ε4 (n = 8; 38.1%); EDS-non-ε3/ε4 (n = 5; 23.8%); non-EDS-ε3/ε4 (n = 6; 28.6%); and non-EDS-non-ε3/ε4 (n = 2; 9.5%). We assessed the differences among the groups by normalized data on a scale ranging from 0 to 100, as aforementioned ( Table 2 ). The EDS-ε3/ε4 group presented the worst cognitive performance, scoring below average in 9 categories ( Figure 1 ): total IQ (18.2 points below), performance IQ (24.6 points), processing-speed index (29.1 points), selective attention (21.8 points), constructional praxis (21.7 points), perceptual organization (37.1 points), visuomotor coordination (23.3 points), and cognitive flexibility (28.8 points) ( Figure 2 ). Polisomnography data are shown in Table 3 .

Table 2. Neuropsychological data of the study sample.

EDS-ε3/ε4
(n = 8; 38.1%)
EDS-non-ε3/ε4
(n = 5; 23.8%)
Non-EDS-ε3/ε4
(n = 6; 28.6%)
Non-EDS-non-ε3/ε4
(n = 2; 9.5%)
Cognitive function Tests Score: mean ± SD n/%* Score: mean ± SD) n/%* Score: mean ± SD) n/%* Score: mean ± SD) n/%*
Selective attention SyS 17.25 ± 7.36 1/12.5% 23.80 ± 5.80 0/0% 22.33 ± 5.80 0/0% 18.50 ± 0.70 0/0%
Divided attention TMT 127.8 ± 68.30 3/37.5% 77.20 ± 48.44 2/40% 114.33 ± 58.89 3/50% 64.50 ± 33.94 0/0%
Constructional praxis Cb 12.75 ± 16.15 7/87.5% 23.40 ± 13.14 3/60% 17.83 ± 15.31 4/66.7% 19.00 ± 4.24 1/50%
Perceptual organization RF 7.00 ± 1.19 5/62.5% 6.60 ± 1.14 1/20% 6.16 ± 2.85 3/50% 9.00 ± 1.41 0/0%
Attention span Dg 7.00 ± 1.19 0/0% 6.60 ± 1.14 0/0% 6.16 ± 2.85 2/33.3% 9.00 ± 1.41 0/0%
Immediate visual memory RFR 13.43 ± 4.29 2/25% 13.40 ± 4.37 1/20% 17.66 ± 6.92 0/0% 16.75 ± 1.76 0/0%
Visuomotor coordination Cd, Cb 24.12 ± 14.42 7/87.5% 34.60 ± 10.36 2/40% 30.66 ± 14.61 3/50% 30.50 ± 7.07 1/50%
Cognitive flexibility TMT-B 201.37 ± 125.36 3/37.5% 109.60 ± 68.75 1/20% 183.83 ± 101.72 3/50% 95.00 ± 56.56 0/0%
Total IQ Vc, Cb, Sm, MR 76.37 ± 17.57 7/87.5% 82.40 ± 13.90 3/60% 86.50 ± 20.40 3/50% 87.50 ± 7.77 1/50%
Verbal IQ Sm, Vc 0.95 ± 0.55 6/75% 1.34 ± 0.75 4/80% 0.80 ± 0.31 3/50% 1.40 ± 0.56 1/50%
Execution IQ Cb, MR, 81.62 ± 18.03 7/87.5% 81.60 ± 10.83 3/60% 89.16 ± 15.35 3/50% 89.00 ± 9.89 1/50%
Processing speed index SyS, Cd 99.87 ± 8.27 1/12.5% 112.20 ± 8.25 0/0% 115.33 ± 16.02 0/0% 108.00 ± 11.31 0/0%

Abbreviations: EDS, excessive daytime sleepiness; Cb, cubes; Cd, Codes; Dg, Digits; IQ, intelligence quotient; MR, Matrix Reasoning; RF, Rey figure; RFR; Rey figure recall; SD, standard deviation; Sm, Similarities; SyS, Symbol Search; TMT, Trail Making test; TMT-B, Trail Making test B; Vc, Vocabulary.

Note: *n/% = % altered.

Figure 2.

Figure 2

Differences in cognitive results among the groups (normalized data).

Table 3. Polysomnography data of the study sample.

All genotypes ApoEε3/ ε4 non-ApoEε3/ε4
Mean SD Mean SD Mean SD
TST (minutes) 346.8 53.0 357.0 58.3 326.3 35.4
WASO (minutes) 75.6 38.2 72.5 35.0 81.7 46.4
Sleep latency (minutes) 16.3 11.8 14.3 11.8 20.4 11.7
REM latency (minutes) 146.6 48.8 127.3 33.4 185.4 53.9
REM (%) 15.2 4.8 16.7 3.8 12.2 5.5
N1 (%) 16.1 8.8 15.5 9.0 17.4 9.0
N2 (%) 54.3 13.3 50.7 12.3 61.5 13.2
N3 (%) 17.2 15.7 17.9 9.7 15.8 24.8
AHI (events per hour) 34.1 15.9 32.6 16.1 37.2 16.3
Sat < 90% (%TST) 0.9 1.6 0.7 1.5 1.5 1.9
PLMI (events per hour) 3.9 13.9 5.6 16.9 0.6 1.6
Arousal index (events per hour) 32.8 16.2 32.5 15.9 33.5 18.0
ESS 9.0 5.2 8.0 5.8 10.9 3.5

Abbreviations: AHI, apnea-hypopnea index; ApoE, apolipoprotein E; ESS, Epworth Sleepiness Scale; N1, non-REM sleep stage 1; N2, non-REM sleep stage 2; N3, non-REM sleep stage 3; PLMI, periodic limb movement index; REM, rapid eye movement sleep; Sat, oxygen saturation; SD, standard deviation; TST, total sleep time; WASO, wake after sleep onset.

Patients with genotype ε3/ε4, with and without EDS, presented a worse performance in divided attention (31.9 points), constructional praxis (21.7), perceptual organization (37.1), and cognitive flexibility (28.8). Those with EDS from both genotype groups presented a worse performance in total IQ (18.2), performance IQ (24.6), and immediate visual memory (19.4). Patients without EDS and genotypes other than ε3/ε4 presented a higher performance in total IQ (18.2), performance IQ (24.6), divided attention (31.1), perceptual organization (37.1), attention span (40.5), and cognitive flexibility (28.8) ( Figure 2 ).

DISCUSSION

Our results suggest that the ApoEε3/ε4 genotype in patients with moderate to severe sleep apnea and EDS is associated with impaired cognitive performance. The mechanisms through which the ε4 allele may affect cognition are not yet understood. According to some studies, 25 individuals with the ε4 allele have a higher incidence of cerebrovascular disease. Other studies 41 report that the presence of the ε4 allele is associated with lower metabolic rates in the posterior cingulate, inferior parietal cortex, and lateral temporal cortex. The ε4 allele is also related to a neurotoxic process that affects the mitochondria, cytoskeleton, and synaptogenesis, impairing cognitive function. 42

In the sample of the present study, similarly to other studies, we found that EDS alone was associated with global cognitive impairment, which was evidenced by lower IQ scores, regardless of the association with the ε4 allele. 16

A proposed mechanism for the etiology of EDS in OSAS is the fragmentation of sleep due to frequent arousals caused by respiratory effort, modifying sleep architecture. 6 Poor sleep quality is associated with memory disturbances. Sleep deprivation affects the hippocampus, compromising memory codification and retention and impairing its interaction with the visual cortex. 43 It can be related to low immediate visual memory performance in patients with EDS.

In the sample of the present study, when EDS and the ApoEε3/ε4 genotype occurred in the same patient, the cognitive disturbance was more intense than when they occurred isolatedly. A possible explanation is that genetic predisposition increases the vulnerability to the prejudicial effects of EDS on cognition. 44

The main weakness of the present study is the small sample size, which limited the power of statistical analysis. We consider it a preliminary study that opens the path for future research in larger samples. Another limitation is the use of the ESS to assess EDS. Although the ESS is a validated and recognized instrument, it uses the patient's subjective perception, with the risk of false positives and false negatives. 31 Future studies with objective methods to assess sleepiness like the multiple sleep latency test and the maintenance of wakefulness test can lead to more accurate results.

In conclusion, the present study found that patients with OSAS, the ApoEε3/ε4 genotype, and EDS had impaired cognitive performance, and that a genetic factor may potentiate the harmful effect of EDS on cognition. Future investigations in this field can contribute to a better understanding and management of the clinical consequences of OSAS.

Funding Statement

Support The present study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).

Conflict of Interest The authors have no conflict of interests to declare.

Authors' Contributions

FMB: hypothesis conception, data collection, analysis; WASM: hypothesis conception, data collection, article writing, analysis; JRH: hypothesis conception, statistics, analysis; GFP, LBCC: hypothesis conception, analysis, review.

References

  • 1.Kryger M H, Roth T, Dement W C. Philadelphia, PA: Saunders/Elsevier; 2011. Principles and Practice of Sleep Medicine. [Google Scholar]
  • 2.Juliano M L, Machado M A, de Carvalho L B. Polysomnographic findings are associated with cephalometric measurements in mouth-breathing children. J Clin Sleep Med. 2009;5(06):554–561. [PMC free article] [PubMed] [Google Scholar]
  • 3.American Academy of Sleep Medicine International Classification of Sleep Disorders3rd ed.Darien, IL: 2014 [Google Scholar]
  • 4.Carvalho L B, Prado L F, Silva L. Cognitive dysfunction in children with sleep-disordered breathing. J Child Neurol. 2005;20(05):400–404. doi: 10.1177/08830738050200050101. [DOI] [PubMed] [Google Scholar]
  • 5.de Carvalho L B, do Prado L B, Ferrreira V R. Symptoms of sleep disorders and objective academic performance. Sleep Med. 2013;14(09):872–876. doi: 10.1016/j.sleep.2013.05.011. [DOI] [PubMed] [Google Scholar]
  • 6.Campostrini D DA, Prado L BF, Prado G F. Obstructive Sleep Apneaand Cardiovascular Diseases (Apneia Obstrutiva do Sono e Doenças Cardiovasculares) Revista Neurociências. 2014;22(01):102–112. doi: 10.4181/RNC.2014.22.930.11p. [DOI] [Google Scholar]
  • 7.Tudorache I F, Trusca V G, Gafencu A V, Apolipoprotein E. Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features. Comput Struct Biotechnol J. 2017;15:359–365. doi: 10.1016/j.csbj.2017.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Piskunowicz M T, Linkowska K, Gołota S, Grzybowski T, Kędziora-Kornatowska K, Borkowska A. The Association of Apolipoprotein E Gene Polymorphism With Cognitive Performance in Nondemented Polish Adults Aged 55 to 75. Int J Aging Hum Dev. 2018;87(02):124–140. doi: 10.1177/0091415017724548. [DOI] [PubMed] [Google Scholar]
  • 9.Gottlieb D J, DeStefano A L, Foley D J. APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. Neurology. 2004;63(04):664–668. doi: 10.1212/01.wnl.0000134671.99649.32. [DOI] [PubMed] [Google Scholar]
  • 10.Gozal D, Capdevila O S, Kheirandish-Gozal L, Crabtree V M. APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. Neurology. 2007;69(03):243–249. doi: 10.1212/01.wnl.0000265818.88703.83. [DOI] [PubMed] [Google Scholar]
  • 11.Kadotani H, Kadotani T, Young T. Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. JAMA. 2001;285(22):2888–2890. doi: 10.1001/jama.285.22.2888. [DOI] [PubMed] [Google Scholar]
  • 12.Suri S, Heise V, Trachtenberg A J, Mackay C E.The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ε2 Neurosci Biobehav Rev 201337(10 Pt 2):2878–2886. 10.1016/j.neubiorev.2013.10.010 [DOI] [PubMed] [Google Scholar]
  • 13.Wu L, Zhao L. ApoE2 and Alzheimer's disease: time to take a closer look. Neural Regen Res. 2016;11(03):412–413. doi: 10.4103/1673-5374.179044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.He K, Kapur V K. Sleep-Disordered Breathing and Excessive Daytime Sleepiness. Sleep Med Clin. 2017;12(03):369–382. doi: 10.1016/j.jsmc.2017.03.010. [DOI] [PubMed] [Google Scholar]
  • 15.Lo J C, Ong J L, Leong R L, Gooley J J, Chee M W. Cognitive Performance, Sleepiness, and Mood in Partially Sleep Deprived Adolescents: The Need for Sleep Study. Sleep. 2016;39(03):687–698. doi: 10.5665/sleep.5552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhou J, Camacho M, Tang X, Kushida C A. A review of neurocognitive function and obstructive sleep apnea with or without daytime sleepiness. Sleep Med. 2016;23:99–108. doi: 10.1016/j.sleep.2016.02.008. [DOI] [PubMed] [Google Scholar]
  • 17.Koehler U, Apelt S, Augsten M. [Daytime sleepiness in patients with Obstructive Sleep Apnoea (OSA) - pathogenetic factors] Pneumologie. 2011;65(03):137–142. doi: 10.1055/s-0030-1255838. [DOI] [PubMed] [Google Scholar]
  • 18.Uyrum E, Balbay O, Annakkaya A N, Gulec Balbay E, Silan F, Arbak P. The relationship between obstructive sleep apnea syndrome and apolipoprotein E genetic variants. Respiration. 2015;89(03):195–200. doi: 10.1159/000369560. [DOI] [PubMed] [Google Scholar]
  • 19.O'Hara R, Schröder C M, Kraemer H C. Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. Neurology. 2005;65(04):642–644. doi: 10.1212/01.wnl.0000173055.75950.bf. [DOI] [PubMed] [Google Scholar]
  • 20.Larkin E K, Patel S R, Redline S, Mignot E, Elston R C, Hallmayer J. Apolipoprotein E and obstructive sleep apnea: evaluating whether a candidate gene explains a linkage peak. Genet Epidemiol. 2006;30(02):101–110. doi: 10.1002/gepi.20127. [DOI] [PubMed] [Google Scholar]
  • 21.Daurat A, Sarhane M, Tiberge M. [Obstructive sleep apnea syndrome and cognition: A review] Neurophysiol Clin. 2016;46(03):201–215. doi: 10.1016/j.neucli.2016.04.002. [DOI] [PubMed] [Google Scholar]
  • 22.Wallace A, Bucks R S. Memory and obstructive sleep apnea: a meta-analysis. Sleep. 2013;36(02):203–220. doi: 10.5665/sleep.2374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Beebe D W, Groesz L, Wells C, Nichols A, McGee K. The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep. 2003;26(03):298–307. doi: 10.1093/sleep/26.3.298. [DOI] [PubMed] [Google Scholar]
  • 24.Olaithe M, Bucks R S, Hillman D R, Eastwood P R. Cognitive deficits in obstructive sleep apnea: Insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation. Sleep Med Rev. 2018;38:39–49. doi: 10.1016/j.smrv.2017.03.005. [DOI] [PubMed] [Google Scholar]
  • 25.Cosentino F I, Bosco P, Drago V. The APOE epsilon4 allele increases the risk of impaired spatial working memory in obstructive sleep apnea. Sleep Med. 2008;9(08):831–839. doi: 10.1016/j.sleep.2007.10.015. [DOI] [PubMed] [Google Scholar]
  • 26.Nikodemova M, Finn L, Mignot E, Salzieder N, Peppard P E. Association of sleep disordered breathing and cognitive deficit in APOE ε4 carriers. Sleep. 2013;36(06):873–880. doi: 10.5665/sleep.2714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Caselli R J, Reiman E M, Hentz J G, Osborne D, Alexander G E, Boeve B F. A distinctive interaction between memory and chronic daytime somnolence in asymptomatic APOE e4 homozygotes. Sleep. 2002;25(04):447–453. [PubMed] [Google Scholar]
  • 28.Bertolazi A N, Fagondes S C, Hoff L S, Pedro V D, Menna Barreto S S, Johns M W. Portuguese-language version of the Epworth sleepiness scale: validation for use in Brazil. J Bras Pneumol. 2009;35(09):877–883. doi: 10.1590/s1806-37132009000900009. [DOI] [PubMed] [Google Scholar]
  • 29.Fu Y, Xu H, Xia Y. Excessive daytime sleepiness and metabolic syndrome in men with obstructive sleep apnea: a large cross-sectional study. Oncotarget. 2017;8(45):79693–79702. doi: 10.18632/oncotarget.19113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Murray B J. Subjective and Objective Assessment of Hypersomnolence. Sleep Med Clin. 2017;12(03):313–322. doi: 10.1016/j.jsmc.2017.03.007. [DOI] [PubMed] [Google Scholar]
  • 31.Johns M W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(06):540–545. doi: 10.1093/sleep/14.6.540. [DOI] [PubMed] [Google Scholar]
  • 32.Gagnon K, Baril A A, Gagnon J F. Cognitive impairment in obstructive sleep apnea. Pathol Biol (Paris) 2014;62(05):233–240. doi: 10.1016/j.patbio.2014.05.015. [DOI] [PubMed] [Google Scholar]
  • 33.Malloy-Diniz L F, Fuentes D, Abrantes S SC, Lasmar V AP, Salgado J V.Teste de aprendizagem auditivo-verbal de Rey RAVLTIn: Malloy-Diniz LF, Fuentes D, Mattos P, Abreu N, eds. et col. Avaliação Neuropsicológica.São Paulo: Artmed; 2010 [Google Scholar]
  • 34.Nascimento E. São Paulo: Casa do Psicólogo; 2004. Escala de inteligência Wechsler para adultos - manual para administração e avaliação. [Google Scholar]
  • 35.Oliveira M S, Rigoni M S. São Paulo: Casa do Psicólogo; 2010. Figuras complexas de Rey: teste de cópia e de reprodução de memória de figuras geométricas complexas. [Google Scholar]
  • 36.Spreen O, Strauss E. New York: Oxford University Press; 1998. A Compendium of Neuropsychological Test. [Google Scholar]
  • 37.Trentini C M, Yates D B, Heck V S. São Paulo: Casa do Psicólogo; 2014. Escala Wechsler Abreviada de Inteligência-WASI: manual. [Google Scholar]
  • 38.Signorell A.DescTools: Tools for descriptive statisticsR package version 0.99.21. 2017 Nov 11. 2017; Fromhttps://cran.r-project.org/package=DescTools.
  • 39.Wickham H.Tidy data J Stat Softw 201459101–23. 10.18637/jss.v059.i1026917999 [DOI] [Google Scholar]
  • 40.Wickham H.Tidyverse: easily install and load ‘tidyverse’ packagesR package version 1.1.1. 2017 Nov 11. 2017; Fromhttps://cran.rproject.org/web/packages/tidyverse/index.html
  • 41.Small G W, Ercoli L M, Silverman D H. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037–6042. doi: 10.1073/pnas.090106797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Zlokovic B V. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol. 2013;70(04):440–444. doi: 10.1001/jamaneurol.2013.2152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Yoo S S, Hu P T, Gujar N, Jolesz F A, Walker M P. A deficit in the ability to form new human memories without sleep. Nat Neurosci. 2007;10(03):385–392. doi: 10.1038/nn1851. [DOI] [PubMed] [Google Scholar]
  • 44.The Multi-Ethnic Study of Atherosclerosis . Johnson D A, Lane J, Wang R. Greater cognitive deficits with sleep-disordered breathing among individuals with genetic susceptibility to Alzheimer Disease. Ann Am Thorac Soc. 2017;14(11):1697–1705. doi: 10.1513/AnnalsATS.201701-052OC. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Arquivos de Neuro-Psiquiatria are provided here courtesy of Academia Brasileira de Neurologia

RESOURCES